While DGAT1 inhibition suppresses tumor growth in various cancers, including glioblastoma [15], melanoma [28], and prostate cancer [17, 18], overexpression of DGAT2 inhibits cell proliferation in hepatocellular carcinoma (HCC) [37, 38]. Here, DGAT2 is linked to hepatocellular carcinoma.